> ## Content Index > Fetch the complete content index at: https://compounded.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # Fifteen Years of Trying to Change the Course of Osteoarthritis - URL: https://compounded.ghost.io/fifteen-years-of-trying-to-change-the-course-of-osteoarthritis/ - Published: 2026-11-04T12:33:00.000Z - Updated: 2026-11-04T12:32:59.000Z - Author: Connor Hayes Osteoarthritis affects tens of millions of American adults and has no treatment that alters what the disease does to a joint. Painkillers help with pain. Physical therapy helps with function. Injections help for a while. When the joint is far enough gone, it gets replaced. Nothing in between slows the cartilage loss itself. Not for want of trying. A review of clinical trials between 2010 and 2024 followed eleven serious candidates through the field. Several failed outright. Several improved pain without touching the joint. One improved the joint without touching the pain. In January, a company announced it had submitted the first candidate to the FDA with a claim to doing both, which makes this a good moment to understand why the previous fifteen years went the way they did. ### From the Lab to the Ledger Osteoarthritis was long described as wear and tear, which is misleading. It is an active process involving the whole joint: cartilage breaking down faster than it is rebuilt, the bone underneath remodelling, and low-grade inflammation in the joint lining driving both. That gives drug developers several plausible targets, and the candidates tested over the past fifteen years have attacked most of them. Enzyme blockers aimed at the proteins that degrade cartilage. Anti-inflammatory biologics aimed at the signalling molecules driving the inflammation. Growth factors aimed at stimulating cartilage repair. A senolytic aimed at clearing damaged cells from the joint. Each had a coherent mechanistic rationale, and most produced nothing measurable in patients. The measurement problem compounds the biology. The classic structural endpoint is joint space width on an X-ray, a stand-in for cartilage thickness measured in fractions of a millimetre and sensitive to how the patient is positioned. MRI measures cartilage directly and is better, but the effects are tiny: the growth factor sprifermin produced a 0.05 mm gain over two years against a 0.07 mm loss on placebo, a real and statistically solid difference that amounts to roughly 2.5 percent of normal cartilage thickness. Then there is the disconnect that defines the field. Sprifermin's structural benefit came with no significant pain improvement in any dose group. Several other candidates improved pain with no structural change. Pain in osteoarthritis is subjective, strongly placebo-responsive, and not linearly related to what the X-ray shows. ### Bio-Pipeline Ledger Lorecivivint: an intra-articular injection given once or twice a year, submitted to the FDA in January for knee osteoarthritis on the strength of a two-year Phase 3 with reported pain, function and joint space results. Under review, with the Phase 3 data announced by the company rather than published at the time of submission. Sprifermin: a growth factor with a demonstrated structural effect on cartilage thickness over five years and no significant pain benefit. No Phase 3 has been started. Cindunistat, SAR113945, GLPG1972, UBX0101 and lutikizumab: five candidates that missed their primary endpoints on pain, structure or both, several with notable adverse effects. Failed. Anti-nerve-growth-factor antibodies: effective analgesics for osteoarthritis pain, classified as painkillers rather than disease-modifying drugs, and carrying concern about rapidly progressing joint destruction. Not approved for this use. Current standard care: exercise and strengthening, weight management, topical and oral analgesics, corticosteroid injections, and joint replacement when warranted. Validated, and still what works. ### The Clinical Reality Check Caution is warranted on the newest candidate, and the reasons are specific rather than reflexive. The two-year Phase 3 results come from a company announcement without published effect sizes or millimetre figures. Earlier trials of the same drug are mixed: a Phase 2a missed its primary pain endpoint and found a benefit only in a post hoc analysis that excluded patients with both knees affected, and a Phase 2b improved pain and function but found no significant joint space difference in any group. A submission is also not an approval, and the FDA has not acted. There is a smaller puzzle worth noting. The company describes the drug as inhibiting two specific kinases, while the independent review describes it as a Wnt pathway inhibitor. Those are not necessarily contradictory, since the pathways connect, but it is a reminder that mechanism descriptions here are less settled than they sound. What has not changed is what helps people now. Strengthening the muscles around an arthritic joint has among the best evidence of anything in musculoskeletal medicine, and it is consistently under-prescribed relative to injections and imaging. Weight management changes joint loading directly. Neither is exciting and both outperform every failed candidate above. The honest framing for anyone with osteoarthritis is that a disease-modifying drug may arrive, that the first one is now in front of regulators, and that the field's history counsels waiting for published data and an approval decision before rearranging expectations. If a clinic offers something described as regenerative or disease-modifying today, outside a trial, it is not one of the agents discussed here. The right conversation is with an orthopaedist or rheumatologist about what is actually available, which remains considerable. ![](https://storage.ghost.io/c/93/20/932004ad-b501-4cef-8a02-28e1473c42cb/content/images/2026/11/osteoarthritis-disease-modifying-drugs-reality-check-2-cinematic.jpg) ###